GlassScriptPhysician profile
Peter Shou You Su
NPI 1164721627
$3,836.13
in general payments reported to CMS, 2019-2025
27 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $189 · 2021: $517 · 2022: $641 · 2023: $959 · 2024: $417 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $652.14 | 2021-2025 | Kyphon Express II Kyphopak Tray, Inceptiv, Intellis Adaptivestim |
| Boston Scientific Corporation | $400.11 | 2019-2025 | General - Pain Management, Patient Trial Kit |
| Medtronic USA, INC. | $366.30 | 2019 | |
| Abbott Laboratories | $350.31 | 2022-2024 | Penta, Proclaim, Octrode |
| Nevro Corp. | $345.75 | 2019-2021 | |
| Janssen Biotech, INC. | $216.50 | 2022-2023 | Stelara, Simponi Aria, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.31 | 2022-2024 | Trulance, Xifaxan, Relistor |
| Nutech Spine, INC. | $187.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.59 | 2022-2025 | Entyvio |
| Si-Bone, INC. | $145.60 | 2022 | |
| Saluda Medical Americas, INC. | $143.46 | 2023 | Evoke Scs |
| Stimwave Technologies Incorporated | $138.89 | 2022 | |
| Scilex Pharmaceuticals INC. | $87.85 | 2019-2020 | |
| Genzyme Corporation | $87.21 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $81.94 | 2023-2024 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $48.20 | 2022-2025 | Suflave, Sutab |
| Ardelyx, INC. | $47.29 | 2023 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $26.73 | 2024 | |
| Spr Therapeutics, INC | $24.31 | 2024 | Sprint Pns System |
| Mannkind Corporation | $21.25 | 2022 | |
| Lucid Diagnostics INC. | $20.92 | 2022 | |
| Forte Bio-Pharma LLC | $17.49 | 2025 | Prolate, Nalocet, Tanlor |
| Organon LLC | $16.81 | 2023 | Renflexis |
| Allergan, INC. | $15.40 | 2020 | |
| Ucb, INC. | $15.26 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.